In the Spotlight...
Towards designing improved cancer immunotherapy targets with a peptide-MHC-I presentation model, HLApollo
The guided fire from within: intratumoral administration of mRNA-based vaccines to mobilize memory immunity and direct immune responses against pathogen to target solid tumors
Sequential STING and CD40 agonism drives massive expansion of tumor-specific T cells in liposomal peptide vaccines
Tumor cells ectopically expressing the membrane-bound form of IL-7 develop an antitumor immune response efficiently in a colon carcinoma model
Previous Digests
What really happens when you block TIGIT and PD-L1 together
January 8, 2025
Both PD-1 and TIGIT are checkpoint molecules known to inhibit the antitumor effects of CD8+ T cells, and blocking them in combination has been shown to have synergistic immunotherapeutic effects. However, the exact mechanism and dynamics of this synergy...
Keeping it local: SynNotch-engineered T cells deliver payloads to specific tissues for a diverse range of applications
December 18, 2024
Immunotherapies are often used to target specific antigens or deliver specific payloads for the treatment of various diseases, but systemic toxicities or side effects in other tissues can limit the safety and efficacy of these treatments. Recently, two teams...
Rab8a restores youthful function in DCs from aged mice
December 11, 2024
With advanced age comes impaired immunity and thus, increased susceptibility to diseases, including infections and cancer. Investigating factors that contribute to this reduced immune functionality, Singh et al. evaluated splenic and bone marrow-derived DCs and found that in aged...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ed Fritsch
Ute Burkhardt
Lauren Hitchings
Gaelle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.
Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT
Current Sponsors
